About Spectrawave
SpectraWAVE Inc. is an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. The company provides advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease affecting more than 300 million people worldwide. SpectraWAVE's flagship HyperVue Imaging System is an intravascular imaging platform that combines DeepOCT (next generation comprehensive optical coherence tomography) and NIRS (near-infrared spectroscopy) into the Enhanced Vascular Imaging (EVI) segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions. The system features rapid setup, acquisition, and automated AI image analysis to support clinical decision-making. The company's X1-FFR is an angiography-derived, AI-enabled physiology solution that calculates Fractional Flow Reserve (FFR) from a single coronary angiogram, providing a non-invasive ischemia assessment and turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows. Both technologies have received FDA clearance as Class 2 medical devices. In December 2025, Royal Philips announced an agreement to acquire SpectraWAVE to expand its image-guided therapy portfolio and integrate SpectraWAVE's technologies with Philips' industry-leading Azurion platform, supporting better outcomes for cardiac patients through the convergence of intravascular imaging, coronary physiology, and AI.
Mission & Story
Mission
The convergence of intravascular imaging, coronary physiology and AI can fundamentally improve how every patient with coronary disease is treated
Clinical Focus
Medical conditions and clinical areas addressed by Spectrawave.
Who It Serves
Milestones & Awards
Recent Milestones
December 2025: Agreement for acquisition by Royal Philips announced. FDA clearances obtained for HyperVue Imaging System (K221257, K230691) and X1-FFR Software (K251355)
Key Partnerships
Social & Media
Latest Updates
News article | July 08, 2026Philips and University of Washington collaborate to accelerate innovation in advanced MRI careMR
1w ago
Press release | July 08, 2026Philips introduces Alturion ultrasound system with AI-powered workflows for high-volume clinical environmentsRadiology
1w ago
Press release | July 07, 2026Philips Sonicare sets new benchmark in oral healthcare with brand's first electric toothbrush powered by on-device AI and real-time spatially aware guidance, helping people brush with greater coverage and confidenceOral healthcare
2w ago
Press release | June 29, 2026University Health in San Antonio selects Philips enterprise monitoring platform to transform patient monitoring and advance system-wide standardization as patient volume growsPatient monitoring
3w ago
Press release | June 17, 2026Philips helps customers rethink flexibility with the IntelliVue Patient Monitor 6000 SeriesPatient monitoring
1mo ago
Company Details
- Founded
- 2017
- Headquarters
- Bedford, MA, USA
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.